1 tering of GD1a or GT1b by using precomplexed antiganglioside Abs.

2 e 7 inhibitors, delta-like protein 3 agents, antiganglioside agents, CD47 inhibitors, and lysine-spec

3 h as nitric oxide, endocaine, cytokines, and antiganglioside antibodies also play significant roles.

4 iatic nerve was performed in the presence of antiganglioside antibodies and fresh human serum as an a

5                           The elimination of antiganglioside antibodies from the circulation through

6                                              Antiganglioside antibodies have long been used in clinic

7          Continuing progress in the field of antiganglioside antibodies is expanding our comprehensio

8 t passively administered and vaccine-induced antiganglioside antibodies prevent outgrowth of micromet

9 ganglioside interactions can be disrupted by antiganglioside antibodies that override MAG-based neuro

10 an-binding proteins including plant lectins, antiganglioside antibodies, bacterial toxins, galectins,

11 -like syndrome, and neuropathy with positive antiganglioside antibodies.

12     Antiglycolipid antibodies, in particular antigangliosides antibodies, are mostly detected in acut

13  of Ranvier is relatively resistant to acute antiganglioside antibody mediated injury over this time

14 lear immune cells and studied the ability of antiganglioside antibody to activate these cells using t

15  exceptionally high cytotoxic potency and an antiganglioside GD2 monoclonal antibody 14G2a.

16 e likely than other GBS patients to have IgG antiganglioside GM1 antibodies and to have had preceding

17                                              Antiganglioside GM1 antibodies were present in a higher

18 s; and (iv) adding highly specific IgG-class antiganglioside mAbs.